A novel intranasal nano-adjuvanted pertussis vaccine with enhanced mucosal delivery and immunogenicity in a rodent model.

IF 1.1 4区医学 Q4 INFECTIOUS DISEASES

Japanese journal of infectious diseases Pub Date : 2025-07-31 DOI:10.7883/yoken.JJID.2024.292

Mohammad Jafari, Leila Omidvar, Aliyar Pirouzi, Saeed Jahandideh, Nader Bagheri, Zahra Amirkhani, Atefeh Alipour, Abbas Salmani, Ali Zarrabi, Meghdad Abdollahpour-Alitappeh, Hosein Shahsavarani

{"title":"A novel intranasal nano-adjuvanted pertussis vaccine with enhanced mucosal delivery and immunogenicity in a rodent model.","authors":"Mohammad Jafari, Leila Omidvar, Aliyar Pirouzi, Saeed Jahandideh, Nader Bagheri, Zahra Amirkhani, Atefeh Alipour, Abbas Salmani, Ali Zarrabi, Meghdad Abdollahpour-Alitappeh, Hosein Shahsavarani","doi":"10.7883/yoken.JJID.2024.292","DOIUrl":null,"url":null,"abstract":"<p><p>The present study developed a novel nano-structured nasal Bordetella pertussis vaccine candidate using encapsulating filamentous haemagglutinin (FHA) and pertussis toxoid (PTd) into N-trimethyl chitosan (TMC) with the help of CpG as an adjuvant and crosslinker (CpG-adjuvanted TMC/PTd-FHA), followed by physicochemical characterization and immune response evaluation after nasal administration. The TMC/CpG/PTd-FHA nanoparticle (NP) exhibited a particle size and zeta potential of 289.4 nm and +25.7 mV, respectively. The antigen/toxoid-loaded NPs exhibited >80% efficacy for encapsulation into polymer matrices, whereas in vitro antigen/toxoid release was found to be 95.18% after 96 hours. High immunization rates were observed in NP-treated mice with increased IgG and secretory IgA levels and proper capability to induce IFN-γ, IL-4, and IL-17 compared with the control group. Overall, nasal administration of the proposed approach, utilizing CpG as an adjuvant and crosslinker, could elicit humoral and Th1-type cellular immune responses, demonstrating promising potential as a vaccine delivery system.</p>","PeriodicalId":14608,"journal":{"name":"Japanese journal of infectious diseases","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese journal of infectious diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7883/yoken.JJID.2024.292","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

The present study developed a novel nano-structured nasal Bordetella pertussis vaccine candidate using encapsulating filamentous haemagglutinin (FHA) and pertussis toxoid (PTd) into N-trimethyl chitosan (TMC) with the help of CpG as an adjuvant and crosslinker (CpG-adjuvanted TMC/PTd-FHA), followed by physicochemical characterization and immune response evaluation after nasal administration. The TMC/CpG/PTd-FHA nanoparticle (NP) exhibited a particle size and zeta potential of 289.4 nm and +25.7 mV, respectively. The antigen/toxoid-loaded NPs exhibited >80% efficacy for encapsulation into polymer matrices, whereas in vitro antigen/toxoid release was found to be 95.18% after 96 hours. High immunization rates were observed in NP-treated mice with increased IgG and secretory IgA levels and proper capability to induce IFN-γ, IL-4, and IL-17 compared with the control group. Overall, nasal administration of the proposed approach, utilizing CpG as an adjuvant and crosslinker, could elicit humoral and Th1-type cellular immune responses, demonstrating promising potential as a vaccine delivery system.

查看原文本刊更多论文

一种新型鼻内纳米佐剂百日咳疫苗，在啮齿动物模型中具有增强的粘膜递送和免疫原性。

本研究将丝状血凝素（FHA）和百日咳类毒素（PTd）包埋在n -三甲基壳聚糖（TMC）中，以CpG为佐剂和交联剂（CpG佐剂TMC/PTd-FHA），经鼻给药后进行理化表征和免疫反应评价，研制了一种新型纳米结构的鼻腔百日咳候选疫苗。TMC/CpG/PTd-FHA纳米颗粒（NP）的粒径和zeta电位分别为289.4 nm和+25.7 mV。抗原/类毒素负载的NPs包封率为约80%，体外96小时抗原/类毒素释放率为95.18%。与对照组相比，np处理小鼠免疫接种率高，IgG和分泌IgA水平升高，诱导IFN-γ、IL-4和IL-17的能力良好。总的来说，利用CpG作为佐剂和交联剂的鼻给药方法可以引发体液和th1型细胞免疫反应，显示出作为疫苗递送系统的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Japanese journal of infectious diseases 医学-传染病学

CiteScore

4.50

自引率

4.50%

发文量

172

审稿时长

2 months

期刊介绍： Japanese Journal of Infectious Diseases (JJID), an official bimonthly publication of National Institute of Infectious Diseases, Japan, publishes papers dealing with basic research on infectious diseases relevant to humans in the fields of bacteriology, virology, mycology, parasitology, medical entomology, vaccinology, and toxinology. Pathology, immunology, biochemistry, and blood safety related to microbial pathogens are among the fields covered. Sections include: original papers, short communications, epidemiological reports, methods, laboratory and epidemiology communications, letters to the editor, and reviews.